Both in their mid-twenties, the two men set up what was initially a fine chemicals business in a Brooklyn factory, using a loan from Pfizer’s father as capital. The company’s first product ...

Pfizer in a statement said it was pleased Do No Harm had decided to voluntarily dismiss the case, which the company said had no merit. The New York-based company changed the program's criteria in ...

incorporated in the year 1950, is a Large Cap company (having a market cap of Rs 20,605.46 Crore) operating in Pharmaceuticals sector. Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals ...

Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.

Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations. On the cost side, Pfizer achieved $4 billion in savings ...

Finally, UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th.

Get Wall Street's Hottest Chart Every Morning Pfizer’s CEO stated that the company revamped its commercial strategy, brought in new leadership, and exceeded market share expectations.

FILE PHOTO: Pfizer company logo is seen at a Pfizer office in Puurs ...

Image Credit: Ververidis Vasilis / Shutterstock. Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to maintain and grow revenues in 2025, says CEO Albert ...